Eventide Asset Management Has Raised Sage Therapeutics (SAGE) Holding by $24.15 Million; As Us Bancorp Del (USB) Stock Value Declined, Holder Merriman Wealth Management Has Decreased Its Position

June 14, 2018 - By Kurt Siggers

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Merriman Wealth Management Llc decreased its stake in Us Bancorp Del (USB) by 26.88% based on its latest 2018Q1 regulatory filing with the SEC. Merriman Wealth Management Llc sold 17,853 shares as the company’s stock declined 9.49% with the market. The institutional investor held 48,564 shares of the major banks company at the end of 2018Q1, valued at $2.45 million, down from 66,417 at the end of the previous reported quarter. Merriman Wealth Management Llc who had been investing in Us Bancorp Del for a number of months, seems to be less bullish one the $83.68B market cap company. The stock decreased 0.25% or $0.13 during the last trading session, reaching $50.95. About 2.86 million shares traded. U.S. Bancorp (NYSE:USB) has declined 2.38% since June 14, 2017 and is downtrending. It has underperformed by 14.95% the S&P500.

Eventide Asset Management Llc increased its stake in Sage Therapeutics Inc (SAGE) by 150% based on its latest 2018Q1 regulatory filing with the SEC. Eventide Asset Management Llc bought 150,000 shares as the company’s stock declined 7.25% with the market. The institutional investor held 250,000 shares of the health care company at the end of 2018Q1, valued at $40.27 million, up from 100,000 at the end of the previous reported quarter. Eventide Asset Management Llc who had been investing in Sage Therapeutics Inc for a number of months, seems to be bullish on the $7.69B market cap company. The stock decreased 2.45% or $4.15 during the last trading session, reaching $165.37. About 449,480 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 127.92% since June 14, 2017 and is uptrending. It has outperformed by 115.35% the S&P500. Some Historical SAGE News: 02/05/2018 – Sage Group 1H Rev GBP899M; 02/05/2018 – Sage Group 1H Net Pft GBP135M; 14/05/2018 – Watercrest Senior Living Group Announces Sage Park Assisted Living and Memory Care is on Schedule to Welcome Residents this Fall; 29/03/2018 – Billboard: Rachael Sage Unveils Howard Jones-Approved Cover of ‘No One Is to Blame’: Exclusive Premiere; 30/03/2018 – Watercrest Senior Living Group Welcomes Jennifer Lopez as Community Relations Director of Sage Park Assisted Living and Memory Care; 30/05/2018 – Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of; 13/04/2018 – Sage Group Lowers FY 2018 Growth Expectations After Slow 1H; 23/05/2018 – SAGE GROUP PLC – INTEGRATION IS CURRENTLY LIVE IN UNITED STATES, CANADA, GERMANY AND UK; 27/03/2018 – FORTUNE Magazine and Great Places to Work Name Sage’s San Jose Sage lntacct Office One of the Bay Area’s Best Workplaces; 23/04/2018 – Sage Therapeutics: Brexanolone IV Received Breakthrough Therapy Designation in Sept 2016

Eventide Asset Management Llc, which manages about $1.15 billion and $2.14B US Long portfolio, decreased its stake in Acceleron Pharma Inc (NASDAQ:XLRN) by 124,000 shares to 529,900 shares, valued at $20.72 million in 2018Q1, according to the filing. It also reduced its holding in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 36,000 shares in the quarter, leaving it with 178,000 shares, and cut its stake in Wave Life Sciences Ltd.

More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Nasdaq.com which released: “Market Trends Toward New Normal in Cheniere Energy Partners, LP, UnitedHealth Group, Anthem, Sage Therapeutics …” on June 12, 2018, also Streetinsider.com with their article: “Pre-Open Movers 06/14: (DEST) (ETSY) (TLGT) Higher; (MIK) (TLRD) (AQMS) Lower (more…)” published on June 14, 2018, Nasdaq.com published: “Here’s Why Sage Therapeutics Rose as Much as 20.3% Today” on June 12, 2018. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: Businesswire.com and their article: “Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression …” published on June 12, 2018 as well as Schaeffersresearch.com‘s news article titled: “Upbeat Drug Data Has Galmed Stock Scaling Nasdaq” with publication date: June 12, 2018.

Among 19 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 17 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 60 analyst reports since September 3, 2015 according to SRatingsIntel. Raymond James initiated Sage Therapeutics, Inc. (NASDAQ:SAGE) on Tuesday, September 13 with “Outperform” rating. The firm earned “Neutral” rating on Wednesday, March 30 by Goldman Sachs. The rating was maintained by Canaccord Genuity on Monday, November 13 with “Buy”. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Needham on Tuesday, September 12. On Thursday, December 7 the stock rating was maintained by BMO Capital Markets with “Buy”. The firm has “Buy” rating by SunTrust given on Thursday, October 19. The firm has “Buy” rating by SunTrust given on Thursday, December 7. The company was maintained on Thursday, August 3 by BMO Capital Markets. The firm earned “Buy” rating on Thursday, November 9 by RBC Capital Markets. The rating was maintained by Leerink Swann on Tuesday, September 12 with “Buy”.

Since January 10, 2018, it had 0 insider buys, and 5 sales for $32.85 million activity. Shares for $9.96M were sold by STARR KEVIN P on Tuesday, April 17. Kanes Stephen also sold $7.80 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shares. Another trade for 7,000 shares valued at $1.08M was made by FRATES JAMES M on Tuesday, May 8. IGUCHI KIMI also sold $4.02M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) on Monday, April 23.

Investors sentiment increased to 1.73 in Q1 2018. Its up 0.24, from 1.49 in 2017Q4. It increased, as 22 investors sold SAGE shares while 56 reduced holdings. 47 funds opened positions while 88 raised stakes. 45.19 million shares or 9.02% more from 41.45 million shares in 2017Q4 were reported. Pub Employees Retirement Association Of Colorado invested in 3,072 shares. Artal Group Inc Sa holds 0.2% or 100,000 shares in its portfolio. Cutter Brokerage reported 5,310 shares or 0.34% of all its holdings. Comml Bank Of New York Mellon owns 1.45M shares. Zeke Advisors Limited Liability Company accumulated 0.03% or 2,023 shares. Vident Advisory Limited Liability Com invested 0.04% in Sage Therapeutics, Inc. (NASDAQ:SAGE). 33,670 are owned by Federated Investors Inc Pa. Pictet Asset Management Ltd owns 389,479 shares. Schwab Charles Inv Mngmt has invested 0.03% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). New York-based Metropolitan Life Ins New York has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Castleark Ltd Liability has invested 0.12% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Rhumbline Advisers holds 0.01% or 40,955 shares. Parallax Volatility Advisers Ltd Partnership invested in 0% or 8,794 shares. Ghost Tree Limited Liability accumulated 0.36% or 11,100 shares. Citigroup has 29,484 shares.

Analysts await U.S. Bancorp (NYSE:USB) to report earnings on July, 18. They expect $1.00 earnings per share, up 17.65% or $0.15 from last year’s $0.85 per share. USB’s profit will be $1.64B for 12.74 P/E if the $1.00 EPS becomes a reality. After $0.95 actual earnings per share reported by U.S. Bancorp for the previous quarter, Wall Street now forecasts 5.26% EPS growth.

Another recent and important U.S. Bancorp (NYSE:USB) news was published by Bizjournals.com which published an article titled: “Four Twin Cities executives make national list of influential leaders in corporate diversity” on June 13, 2018.

Investors sentiment decreased to 0.87 in 2018 Q1. Its down 0.09, from 0.96 in 2017Q4. It dived, as 67 investors sold USB shares while 470 reduced holdings. 95 funds opened positions while 370 raised stakes. 1.17 billion shares or 1.27% less from 1.18 billion shares in 2017Q4 were reported. Moreover, Ghp Inv has 0.43% invested in U.S. Bancorp (NYSE:USB) for 60,696 shares. Moreover, Bessemer Group Inc has 0.94% invested in U.S. Bancorp (NYSE:USB). 65,480 are owned by Sns Fincl Group Limited Liability Company. Inverness Counsel Lc has invested 0.81% in U.S. Bancorp (NYSE:USB). Abner Herrman & Brock Llc holds 0.43% in U.S. Bancorp (NYSE:USB) or 53,636 shares. Tci Wealth Inc invested 0.15% of its portfolio in U.S. Bancorp (NYSE:USB). Prospector Prtn Limited Liability Company reported 1.45% of its portfolio in U.S. Bancorp (NYSE:USB). Principal Fincl Inc holds 0.28% of its portfolio in U.S. Bancorp (NYSE:USB) for 5.77M shares. Madison Investment Holdings reported 2.00 million shares. Pekin Singer Strauss Asset Il accumulated 46,329 shares or 0.43% of the stock. Kcm Investment Advsr Lc has 0.37% invested in U.S. Bancorp (NYSE:USB) for 119,771 shares. Amica Retiree Med Tru, Rhode Island-based fund reported 13,757 shares. American Intl Inc reported 758,679 shares. Century Cos invested in 10.03 million shares or 0.51% of the stock. Somerset Limited reported 279,667 shares or 12.71% of all its holdings.

Since February 20, 2018, it had 0 insider buys, and 5 insider sales for $9.81 million activity. The insider GODRIDGE LESLIE V sold $1.35M. von Gillern Jeffry H. had sold 13,641 shares worth $750,528. Another trade for 20,000 shares valued at $1.10M was sold by Elmore John R.. Parker P.W. sold $5.51M worth of U.S. Bancorp (NYSE:USB) on Tuesday, February 20.

Among 33 analysts covering U.S. Bancorp (NYSE:USB), 12 have Buy rating, 4 Sell and 17 Hold. Therefore 36% are positive. U.S. Bancorp had 96 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Friday, January 22 by RBC Capital Markets. The stock has “Outperform” rating by RBC Capital Markets on Thursday, October 20. On Wednesday, July 22 the stock rating was initiated by Canaccord Genuity with “Buy”. The rating was upgraded by Vining Sparks on Friday, April 6 to “Buy”. Robert W. Baird maintained the shares of USB in report on Tuesday, September 5 with “Hold” rating. The stock has “Hold” rating by Keefe Bruyette & Woods on Wednesday, September 13. The rating was maintained by JP Morgan with “Neutral” on Wednesday, November 1. Susquehanna maintained U.S. Bancorp (NYSE:USB) on Wednesday, April 18 with “Hold” rating. The firm has “Hold” rating by Sandler O’Neill given on Wednesday, January 17. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Friday, October 13 report.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>